Nothing Special   »   [go: up one dir, main page]

CY1114441T1 - Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα - Google Patents

Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα

Info

Publication number
CY1114441T1
CY1114441T1 CY20131100841T CY131100841T CY1114441T1 CY 1114441 T1 CY1114441 T1 CY 1114441T1 CY 20131100841 T CY20131100841 T CY 20131100841T CY 131100841 T CY131100841 T CY 131100841T CY 1114441 T1 CY1114441 T1 CY 1114441T1
Authority
CY
Cyprus
Prior art keywords
compounds
immunoxy
peptidomimetics
connective
immunogenic
Prior art date
Application number
CY20131100841T
Other languages
English (en)
Inventor
Peter Timmerman
Wouter Cornelis Puijk
Jelle Wouter Slootstra
Dijk Evert Van
Robert Hans Meloen
Original Assignee
Pepscan Systems B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepscan Systems B.V. filed Critical Pepscan Systems B.V.
Publication of CY1114441T1 publication Critical patent/CY1114441T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση παρέχει μέσα και μεθόδους για παρασκευή ενώσεων κατάλληλων για εξέταση για την παρουσία ή/και για την πιστοποίηση ανοσογονικής ένωσης ή/και συνδετικής ένωσης που ενδιαφέρει. Ανοσογονικές ενώσεις και συνθέσεις επίσης παρέχονται εδώ, καθώς επίσης πεπτιδομιμητικά μελών της οικογένειας κυστίνης-κόμβου.
CY20131100841T 2005-01-24 2013-09-30 Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα CY1114441T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05075174 2005-01-24
EP05077896 2005-12-16
EP06701606.3A EP1844337B1 (en) 2005-01-24 2006-01-24 Binding compounds, immunogenic compounds and peptidomimetics

Publications (1)

Publication Number Publication Date
CY1114441T1 true CY1114441T1 (el) 2016-08-31

Family

ID=36168379

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100841T CY1114441T1 (el) 2005-01-24 2013-09-30 Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα

Country Status (13)

Country Link
US (1) US7863239B2 (el)
EP (1) EP1844337B1 (el)
JP (1) JP5372380B2 (el)
AU (1) AU2006206848B2 (el)
CA (1) CA2595902C (el)
CY (1) CY1114441T1 (el)
DK (1) DK1844337T3 (el)
ES (1) ES2428869T3 (el)
NZ (1) NZ560504A (el)
PL (1) PL1844337T3 (el)
PT (1) PT1844337E (el)
SI (1) SI1844337T1 (el)
WO (1) WO2006078161A1 (el)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2929891B1 (en) * 2004-04-13 2020-03-11 St Vincent's Hospital Sydney Limited Method for modulating appetite
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
US20100322945A1 (en) * 2006-07-26 2010-12-23 Peter Timmerman Immunogenic compounds and protein mimics
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
AU2007333846B2 (en) 2006-12-14 2014-01-23 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
BRPI0807578A2 (pt) 2007-02-23 2021-06-15 Aileron Therapeutics, Inc. macrociclo peptidomimético, composto, kit e métodos para sintetizar um macrociclo peptidomimético
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CA2714477C (en) * 2008-02-05 2018-10-16 Medical Research Council Methods and complexis comprising phage particles
JPWO2009107771A1 (ja) * 2008-02-27 2011-08-04 国立大学法人大阪大学 金−酸化鉄複合ナノ粒子を用いたペプチドの合成方法
CN102256615A (zh) 2009-01-14 2011-11-23 爱勒让治疗公司 拟肽大环化合物
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012083078A2 (en) 2010-12-15 2012-06-21 The Research Foundation Of State University Of New York Croos-linked peptides and proteins, methods of making same, and uses thereof
JP6157461B2 (ja) 2011-06-30 2017-07-05 ジェンザイム・コーポレーション Ｔ細胞活性化の阻害剤
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
EP2764140B1 (en) * 2011-10-07 2017-08-30 Bicycle Therapeutics Limited Modulation of structured polypeptide specificity
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
EP2794636A1 (en) * 2011-12-19 2014-10-29 Janssen R&D Ireland Hiv membrane fusion inhibitors
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
WO2013173755A1 (en) * 2012-05-18 2013-11-21 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2014215639B2 (en) 2013-01-25 2017-03-23 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
WO2014207534A2 (en) * 2013-06-25 2014-12-31 Sépia Pesquisa E Desenvolvimento Bradykinin receptor modulators and use thereof
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
WO2015166036A1 (en) 2014-05-02 2015-11-05 Morphosys Ag Peptide libraries
RS62428B1 (sr) 2014-06-12 2021-11-30 Ra Pharmaceuticals Inc Modulacija aktivnosti komplementa
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
KR102672706B1 (ko) 2014-10-31 2024-06-07 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하기 위한 조성물 및 사용 방법
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
HUE053697T2 (hu) * 2015-09-17 2021-07-28 Histide Ag Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása
JP7145503B2 (ja) * 2015-09-17 2022-10-03 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
RS60134B1 (sr) 2015-12-16 2020-05-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201600903D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
EP3436068A4 (en) 2016-03-31 2020-01-15 NGM Biopharmaceuticals, Inc. BINDING PROTEINS AND METHOD FOR USE THEREOF
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
CN110506049B (zh) 2016-12-23 2024-08-16 拜斯科技术开发有限公司 用于结合mt1-mmp的肽配体
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
BR112020014576A2 (pt) 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
WO2019193328A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US11084857B2 (en) * 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
GB201820325D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
SG11202106081YA (en) 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
US20220088207A1 (en) 2018-12-21 2022-03-24 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
US20220135614A1 (en) 2019-03-04 2022-05-05 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
EP4038096A1 (en) 2019-10-03 2022-08-10 BicycleTX Limited Heterotandem bicyclic peptide complexes
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
EP4132481A1 (en) 2020-04-06 2023-02-15 BicycleTX Limited Bicyclic peptide ligands specific for tslp
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
CN116018349A (zh) 2020-05-15 2023-04-25 拜斯科技术开发有限公司 抗感染的双环肽配体
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
EP4263583A2 (en) 2020-12-19 2023-10-25 Olaplex, Inc. Compositions and method of use for hair straightening and shaping
CN117120459A (zh) 2021-01-08 2023-11-24 拜斯科技术开发有限公司 抗感染双环肽配体
US20240083945A1 (en) 2021-01-08 2024-03-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
AU2022206101A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Anti-infective bicyclic peptide ligands
KR20230141794A (ko) 2021-01-08 2023-10-10 바이사이클티엑스 리미티드 헤테로탠덤 바이사이클릭 펩티드 복합체
WO2022148968A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CA3206525A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CN118103075A (zh) 2021-09-03 2024-05-28 拜斯科技术开发有限公司 双环肽毒素偶联物及其中间体的合成
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
EP4469081A1 (en) 2022-01-24 2024-12-04 Cambridge Enterprise Limited Tau therapy
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
WO2025046244A1 (en) 2023-09-01 2025-03-06 Bicycletx Limited Tlr3 binding bicyclic peptide ligands
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
FR2839452A1 (fr) 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
GB0213878D0 (en) 2002-06-17 2002-07-31 Protherics Plc Use
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound

Also Published As

Publication number Publication date
EP1844337B1 (en) 2013-07-03
CA2595902C (en) 2017-08-22
PL1844337T3 (pl) 2013-12-31
JP2008529482A (ja) 2008-08-07
AU2006206848B2 (en) 2012-05-31
US7863239B2 (en) 2011-01-04
SI1844337T1 (sl) 2013-11-29
CA2595902A1 (en) 2006-07-27
EP1844337A1 (en) 2007-10-17
AU2006206848A1 (en) 2006-07-27
US20080313749A1 (en) 2008-12-18
JP5372380B2 (ja) 2013-12-18
DK1844337T3 (da) 2013-09-30
NZ560504A (en) 2009-07-31
PT1844337E (pt) 2014-04-03
ES2428869T3 (es) 2013-11-12
WO2006078161A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
CY1114441T1 (el) Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα
CY1122646T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
CY1118169T1 (el) Λεμφοκυτταρικο αντιγονο 75 (ly75)
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
EA200801414A1 (ru) Кальцилитические соединения
EA200702643A1 (ru) Антитела, связывающие tweak
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
EA200700225A1 (ru) Аналоги тетрапептида
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20092611L (no) Krystallinsk faststoff Rasagilin base
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ATE502048T1 (de) Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY29233A1 (es) Procedimiento para preparar derivados condensados de piperazin-2-ona
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
PA8792401A1 (es) Fenilendiaminas